Romosozumab|cas:909395-70-6|西域试剂

Romosozumab,96.58%

产品编号：Bellancom-P9982| CAS NO：909395-70-6

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P9982	￥2800.00	杭州北京（现货）
Bellancom-P9982	￥7000.00	杭州北京（现货）
Bellancom-P9982	￥11200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Romosozumab

产品介绍

Romosozumab 是人源化抗硬化蛋白单克隆抗体，可通过抑制骨吸收促进骨形成和抑制骨硬化素。Romosozumab 可用于骨质疏松的研究。

生物活性

Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.

体外研究

体内研究

Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys.
Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass, architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male cynomolgus monkeys
Dosage:	30 mg/kg
Administration:	Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
Result:	Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male cynomolgus monkeys
Dosage:	30 mg/kg
Administration:	Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
Result:	Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.